Tauopathy-focused Asceneuron secures $30m
This article was originally published in Scrip
Asceneuron, a startup biotech company with ambitions to take the lead in neurodegeneration drug development, has managed to secure CHF30m (US$30.6m) to advance its tauopathy drug. Investors have clearly seen potential in the company despite a lack of clarity on the relationship between the tau protein and neurodegeneration.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.